MedTrace Logo

The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant

NCT02595983 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-03-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to evaluate the safety and effectiveness of revusiran (ALN-TTRSC) in adults with transthyretin-mediated amyloidosis (ATTR), whose disease has continued to worsen after liver transplantation. Dosing has been discontinued; patients are being followed-up for safety.

Conditions

  • Transthyretin (TTR)-Mediated Amyloidosis
  • Familial Amyloidotic Polyneuropathy (FAP)
  • ATTR Amyloidosis
  • Familial Amyloid Neuropathies

Interventions

DRUG

Revusiran

500mg Revusiran by subcutaneous (sc) injection

Sponsors & Collaborators

Principal Investigators

  • John Vest, MD · Alnylam Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-02-06
Completion
2017-02-06

Countries

  • France
  • Germany
  • Portugal
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02595983 on ClinicalTrials.gov